Clostridium difficile: Changing epidemiology, treatment and infection prevention measures

Current Infectious Disease Reports

Volumn 14, Issue 6, 2012, Pages 612-619

  Cecil, Jane A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CDI; Clostridium difficile; Colitis; Epidemiology; NAP 1; Toxin; Transmission

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; FIDAXOMICIN; GLUTAMATE DEHYDROGENASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METRONIDAZOLE; MONOCLONAL ANTIBODY; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; TOXIN ANTIBODY; VANCOMYCIN;

BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOTHERAPY; BACTERIUM ISOLATE; BIOLOGICAL THERAPY; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; EPIDEMIC; HUMAN; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MICROFLORA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; TOXIN SYNTHESIS; TREATMENT DURATION; TREATMENT INDICATION;

EID: 84870519083     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0298-9     Document Type: Review

References (80)

1. Finney J. Gastro-enterostomy for cicatrizing ulcer of the pylorus. Bull Johns Hopkins Hosp. 1893;4:53-5.
2. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:390-402.
3. Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. Clindamycin-Associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis. 1977;136(5):701-5.
4. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-Associated pseudomembranous colitis due to toxinproducing Clostridia. N Engl J Med. 1978;298(10):531-4.
5. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-Associated enteric disease. Ann InternMed. 2006;145:758-64.
6. McDonald LC, Owings M, Jernigan JB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409-15.
7. Elixhauser A, Jhung MA. Clostridium difficile-Associated disease in US Hospitals, 1993-2005. HCUP Statistical Brief no. 50. Agency for Healthcare Research and Quality, Rockville, MD http://www.hcupus. ahrq.gov/reports/ statbriefs/sb50.pdf (2008). Accessed 25 Sep 2012.
8. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-Associated Clostridium difficile infection and of healthcare-Associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32(4):387-90.
9. Campbell RJ, Giljahn L, Kim Machesky K, et al. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol. 2009;30:526-33.
10. Dubberke ER, Reske KA, Olsen MA, et al. Short-And long-Term attributable costs of Clostridium difficile-Associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46(4):497-504.
11. Dubberke ER, Butler AM, Reske KA, et al. Attributable outcomes of endemic Clostridium difficile-Associated disease in nonsurgical patients. Emerg Infect Dis. 2008;14(7):1031-8.
12. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2007;13:1417-9.
13. United Kingdom Office for National Statistics. Deaths involving Clostridium difficile: England and Wales, 2006 to 2010. http://www.ons.gov.uk/ ons/rel/subnational-health2/deaths-involvingclostridium-difficile/2006-To-2010/ statistical-bulletin-download.pdf. Accessed 25 Sep 2012.
14. Pépin JL, Valiquette ME, Alary ME, et al. Clostridium difficileassociated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern disease severity. CMAJ. 2004;17:466-72.
15. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-41.
16. Denève C, Janoir C, Poilane I, et al. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents. 2009;33 Suppl 1:S24-8.
17. Hensgens MP, Goorhuis A, Notermans DW, et al. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro Surveill. 2009;14(45):19402. Pii.
18. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N Eng J Med. 2005;353:2442-9.
19. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-84.
20. MacCannell DR, Louie TJ, Gregson DB, et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol. 2006;44:2147-52.
21. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficileassociated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-60.
22. Kallen AJ, Thompson A, Ristaino P, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile Infection at a community hospital. Infect Control Hosp Epidemiol. 2009;30:264-72. Very interesting paper examining the benefit of fluoroquinolone restriction on rates of CDI associated with the NAP-1 strain.
23. Barth H, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev. 2004;68:373-402.
24. Barbut F, Decré D, Lalande V, et al. Clinical features of Clostridium difficile associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol. 2005;54:181-5.
25. Geric B, Carman RJ, Rupnik M, et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis. 2006;193:1143-50.
26. Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File, 1999-2007. CDC WONDER On-line Database, compiled from Compressed Mortality File 1999-2007 Series 20 No. 2M, 2010. http://wonder.cdc.gov/cmf-icd10.html. Accessed Sep 2012.
27. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-Associated disease in populations previously at low risk -four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1201-5.
28. Rouphael NG, O'Donnell JA, Bhatnagar J, et al. Clostridium difficile-Associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol. 2008;198:e1-6.
29. Bryant K, McDonald LC. Clostridium difficile infections in children. Pediatr Infect Dis J. 2009;28:145-6.
30. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by epidemic BI/NAP1/027 strain. Gastroenterology. 2009;136:1913-24.
31. Dial S, Kezouh A, Dascal S, et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ. 2008;179:767-72.
32. Lambert PJ, Dyck M, Thompson LH, Hammond GW. Population based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol. 2009;30(10):945-51.
33. Kutty PK, Woods CW, Sena AC, et al. Risk factors for and estimated incidence of community-Associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis. 2010;16 (2):197-204. Interesting paper documenting the emergence of CDI in community-based settings and associated risk factors.
34. Bhangu A, Czapran A, Bhangu S, Pillay D. Optimum timing of blood tests for monitoring patients with Clostridium difficileassociated diarrhea. J Investig Med. 2010;58:621-4.
35. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile-Associated disease. Emerg Infect Dis. 2009;15(3):415-22. Important paper identifying risk factors and clinical characteristics of patients with severe CDI to help guide treatment.
36. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-55. The most recent treatment guidelines for CDI, a very useful reference though published prior to the FDA approval of fidaxomicin.
37. Bartlett JG. Clostridium difficile: progress and challenges. Ann N Y Acad Sci. 2010;1213:62-9.
38. Schmidt ML, Gilligan PH. Clostridium difficile testing algorithms: what is practical and feasible? Anaerobe. 2009;15:270-3.
39. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15:1053-66.
40. Mohan SS, McDermott BP, Parchuri S, Cunha BA. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med. 2006;119:e7-8.
41. Sharp SE, Ruden LO, Pohl JC, et al. Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in the rapid simple diagnosis of Clostridium difficile disease. J Clin Microbiol. 2010;48:2082-6.
42. Quinn CD, Sefers SE, Babiker W, et al. C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens. J Clin Microbiol. 2010;48:603-5.
43. Tenover FC, Novak-Weekley S, Woods CW, et al. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol. 2010;48(10):3719-24.
44. Peterson LR, Manson RU, Paule SM, et al. Detection of toxigenic Clostridium difficile in stool samples by real-Time polymerase chain reaction for the diagnosis of C. difficile-Associated diarrhea. Clin Infect Dis. 2007;45:1152-60.
45. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-Time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol. 2009;47:373-8.
46. Deshpande A, Pasupuleti V, Rolston DD, et al. Diagnostic accuracy of real-Time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a meta-Analysis. Clin Infect Dis. 2011;53(7):e81-90.
47. American Society for Microbiology. A practical guidance document for the laboratory detection of toxigenic Clostridium difficile. September 2010. http://www.asm.org/images/pdf/Clinical/clostridiumdifficile9-21.pdf. Accessed 25 Sep 2012. Provides useful guidance on recommended CDI testing procedures.
48. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridiumdifficile-Associated diarrhoea and colitis. Lancet. 1983;2:1043-6.
49. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586-90.
50. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-7.
51. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-Associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5:549-57.
52. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-7. Important study demonstrating superiority of vancomycin over metronidazole in patients with severe CDI, leading in part to new treatment guidelines.
53. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245:267-72.
54. Gash K, Brown E, Pullyblank A. Emergency subtotal colectomy for fulminant Clostridium difficile colitis -is a surgical solution considered for all patients? Ann R Coll Surg Engl. 2010;92:56-60.
55. Tannock GW, Muro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology. 2010;156:3354-9.
56. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(S2):S132-42.
57. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-31. Pivotal trial leading to FDA approval of fidaxomicin for the treatment of CDI.
58. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(S2): S154-61. This is the only study to date evaluating the efficacy of fidaxomicin for the treatment of recurrent CDI.
59. Clinical Trials.gov. http://clinicaltrials.gov/ct2/results? term0fidaxomicin. Accessed 25 Sep 2012.
60. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53:440-7. Interesting study demonstrating the effect of concomitant antibiotics, even very brief exposure, on CDI treatment outcomes.
61. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-75.
62. Kelly CP, LaMont JT. Clostridium difficile -more difficult than ever. N Engl J Med. 2008;359:1932-40.
63. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-Associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-8.
64. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197-205. Exciting paper with promising results for humoral based therapy for CDI. 65. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-7.
65. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-93.
66. Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents. 2009;33:4-7.
67. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with non-Toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents. 2009;33(S1): S46-50. Interesting study demonstrating benefit of using nontoxigenic Clostridium difficile strains to prevent CDI from toxigenic strains in hamsters during antibiotic administration.
68. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-Term follow up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:1079-87.
69. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994-1002.
70. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med. 1990;88:137-40.
71. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29(S1):S81-92.
72. Association for Professionals in Infection Control and Epidemiology, Inc. Guide to the elimination of Clostridium difficile in healthcare settings. November 2008. http://www.apic.org/Resource-/EliminationGuideForm/5de5d1c1-316a- 4b5e-b9b4-c3fbeac1b53e/File/APIC-Cdiff-Elimination-Guide.pdf. Accessed 25 Sep 2012
73. Edmonds S, Kasper D, Zepka C, et al. Clostridium difficile and hand hygiene: spore removal effectiveness of handwash products. Presented at SHEA 2009; Abstract 43.
74. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010;31(1):21-7.
75. Brooks SE, Veal RO, Kramer M, et al. Reduction in the incidence of Clostridium difficile-Associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol. 1992;13(2):98-103.
76. de Gialluly C, Morange V, de Gialluly E, et al. Blood pressure cuff as a potential vector of pathogenic microorganisms: a prospective study in a teaching hospital. Infect ControlHosp Epidemiol. 2006;27(9):940-3.
77. Vajravelu RK, Guerrero DM, Jury LA, Donskey CJ. Evaluation of stethoscopes as vectors of Clostridium difficile and methicillin-resistant Staphylococcus aureus. Infect ControlHosp Epidemiol. 2012;33(1):96-8.
78. Mayfield JL, Leet T, Miller J, Mundy L. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis. 2000;31 (4):995-1000.
79. Wilcox MF, Fawley WN, Wigglesworth N, et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect. 2003;54:109-14.
80. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother. 2007;59:990-5.